Armata Pharmaceuticals Inc
AMEX:ARMP
Armata Pharmaceuticals Inc
Free Cash Flow
Armata Pharmaceuticals Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Armata Pharmaceuticals Inc
AMEX:ARMP
|
Free Cash Flow
-$36.3m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-12%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Free Cash Flow
$15.4B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
3%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Free Cash Flow
$9.6B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Free Cash Flow
$10.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Free Cash Flow
-$1.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-7%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Free Cash Flow
$3B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
12%
|
CAGR 10-Years
30%
|
|
Armata Pharmaceuticals Inc
Glance View
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.
See Also
What is Armata Pharmaceuticals Inc's Free Cash Flow?
Free Cash Flow
-36.3m
USD
Based on the financial report for Mar 31, 2025, Armata Pharmaceuticals Inc's Free Cash Flow amounts to -36.3m USD.
What is Armata Pharmaceuticals Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-12%
Over the last year, the Free Cash Flow growth was 23%. The average annual Free Cash Flow growth rates for Armata Pharmaceuticals Inc have been -17% over the past three years , -16% over the past five years , and -12% over the past ten years .
You don't have any saved screeners yet